Ursolic Acid Potentializes Conventional Therapy in Experimental Leishmaniasis (2020)
- Authors:
- Autor USP: LAURENTI, MARCIA DALASTRA - FM
- Unidade: FM
- DOI: 10.3390/pathogens9100855
- Subjects: LEISHMANIOSE VISCERAL; LEISHMANIOSE CUTÂNEA
- Agências de fomento:
- National Council for Scientific and Technological Development (CNPq)National Council for Scientific and Technological Development (CNPq)
- Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2016/10324-6, 2016/00468-0, 2018/07885-1, 2018/24077-6, HCFMUSP-LIM50]
- Language: Inglês
- Imprenta:
- Source:
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
JESUS, Jessica Adriana et al. Ursolic Acid Potentializes Conventional Therapy in Experimental Leishmaniasis. Pathogens, v. 9, n. 10, 2020Tradução . . Disponível em: https://doi.org/10.3390/pathogens9100855. Acesso em: 20 jan. 2026. -
APA
Jesus, J. A., Silva, T. N. F. da, Yamamoto, E. S., Lago, J. H. G., Laurenti, M. D., & Passero, L. F. D. (2020). Ursolic Acid Potentializes Conventional Therapy in Experimental Leishmaniasis. Pathogens, 9( 10). doi:10.3390/pathogens9100855 -
NLM
Jesus JA, Silva TNF da, Yamamoto ES, Lago JHG, Laurenti MD, Passero LFD. Ursolic Acid Potentializes Conventional Therapy in Experimental Leishmaniasis [Internet]. Pathogens. 2020 ; 9( 10):[citado 2026 jan. 20 ] Available from: https://doi.org/10.3390/pathogens9100855 -
Vancouver
Jesus JA, Silva TNF da, Yamamoto ES, Lago JHG, Laurenti MD, Passero LFD. Ursolic Acid Potentializes Conventional Therapy in Experimental Leishmaniasis [Internet]. Pathogens. 2020 ; 9( 10):[citado 2026 jan. 20 ] Available from: https://doi.org/10.3390/pathogens9100855 - Improving protection against visceral leishmaniasis by heterologous prime-boost vaccination based on DNA and insect-derived recombinant proteins
- Serological cross-reactivity of Trypanosoma cruzi, Ehrlichia canis, Toxoplasma gondii, Neospora caninum and Babesia canis to Leishmania infantum chagasi tests in dogs
- Coinfection of Leishmania chagasi with Toxoplasma gondii, Feline Immunodeficiency Virus (FIV) and Feline Leukemia Virus (FeLV) in cats from an endemic area of zoonotic visceral leishmaniasis
- Evaluation of Rhamnetin as an Inhibitor of the Pharmacological Effect of Secretory Phospholipase A2
- Feline leishmaniasis in the municipality of Araçatuba, São Paulo, Brazil
- Alterações eletromiográficas e histopatológicas da musculatura de cães naturalmente infectados por Leishmania infantum
- Ocorrência de leishmaniose em gatos de área endêmica para leishmaniose visceral
- Canine visceral leishmaniasis: Performance of a rapid diagnostic test (Kalazar Detect™) in dogs with and without signs of the disease
- Ultradeformable Lipid Vesicles Localize Amphotericin B in the Dermis for the Treatment of Infectious Skin Diseases
- Cutaneous Leishmaniasis in dogs: is high seroprevalence indicative of a reservoir role?
Informações sobre o DOI: 10.3390/pathogens9100855 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
